Amikacin penetration into synovial fluid during treatment of septic arthritis.
The concentration of amikacin from simultaneous synovial fluid and serum samples was measured on four separate occasions in a patient treated for Serratia marcescens septic arthritis. Synovial fluid levels were between 12.5 and 24.4 micrograms/ml, with concurrent serum levels of 12.1-21.0 micrograms/ml. Parenterally administered amikacin readily distributed into synovial fluid. Failure to eradicate the patient's Serratia septic arthritis with amikacin and daily arthrocentesis may have been a result of inactivation of the antibiotic arising from acidosis occurring in the synovial fluid.
D000368:Aged; D000583:Amikacin / Q000378:metabolism*; D001170:Arthritis, Infectious / Q000188:drug therapy*; D004756:Enterobacteriaceae Infections / Q000188:drug therapy; D006801:Humans; D007612:Kanamycin / Q000031:analogs & derivatives*; D008297:Male; D012706:Serratia marcescens; D013582:Synovial Fluid / Q000378:metabolism*
D007612:Kanamycin; D000583:Amikacin